EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Revenue
EyePoint Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Revenue
$46m
|
CAGR 3-Years
10%
|
CAGR 5-Years
59%
|
CAGR 10-Years
36%
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$60.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
See Also
What is EyePoint Pharmaceuticals Inc's Revenue?
Revenue
46m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Revenue amounts to 46m USD.
What is EyePoint Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
36%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for EyePoint Pharmaceuticals Inc have been 10% over the past three years , 59% over the past five years , and 36% over the past ten years .